Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
24 04 2020
Historique:
received: 09 03 2020
revised: 08 04 2020
accepted: 20 04 2020
entrez: 30 4 2020
pubmed: 30 4 2020
medline: 7 4 2021
Statut: epublish

Résumé

Recent studies have raised the possibility of a role for lipoproteins, including high-density lipoprotein cholesterol (HDLc), in abdominal aortic aneurysm (AAA). The study was conducted in plasmas from 39 large size AAA patients (aortic diameter > 50 mm), 81 small/medium size AAA patients (aortic diameter between 30 and 50 mm) and 38 control subjects (aortic diameter < 30 mm). We evaluated the potential of HDL-mediated macrophage cholesterol efflux (MCE) to predict AAA growth and/or the need for surgery. MCE was impaired in the large aortic diameter AAA group as compared with that in the small/medium size AAA group and the control group. However, no significant difference in HDL-mediated MCE capacity was observed in 3 different progression subgroups (classified according to growth rate < 1 mm per year, between 1 and 5 mm per year or >5 mm per year) in patients with small/medium size AAA. Moreover, no correlation was found between MCE capacity and the aneurysm growth rate. A multivariate Cox regression analysis revealed a significant association between lower MCE capacity with the need for surgery in all AAA patients. Nevertheless, the significance was lost when only small/medium size AAA patients were included. Our results suggest that MCE, a major HDL functional activity, is not involved in AAA progression.

Identifiants

pubmed: 32344702
pii: biom10040662
doi: 10.3390/biom10040662
pmc: PMC7226271
pii:
doi:

Substances chimiques

Cholesterol, HDL 0
Cholesterol 97C5T2UQ7J

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : FIS 18-00164
Pays : International
Organisme : Instituto de Salud Carlos III
ID : CIBERDEM
Pays : International
Organisme : Instituto de Salud Carlos III
ID : CIBERCV
Pays : International
Organisme : Ministerio de Economía y Competitividad
ID : SAF2016-80843-R
Pays : International
Organisme : "la Caixa" Foundation
ID : HR17-00247
Pays : International

Références

Lancet. 2005 Apr 30-May 6;365(9470):1577-89
pubmed: 15866312
JAMA Cardiol. 2018 Jan 1;3(1):26-33
pubmed: 29188294
Cardiovasc Res. 2011 Apr 1;90(1):18-27
pubmed: 21037321
Health Technol Assess. 2013 Sep;17(41):1-118
pubmed: 24067626
PLoS One. 2010 Jul 23;5(7):e11765
pubmed: 20668705
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2678-86
pubmed: 23023368
Scand J Surg. 2008;97(2):105-9; discussion 109
pubmed: 18575024
Eur J Vasc Endovasc Surg. 2019 Jan;57(1):8-93
pubmed: 30528142
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Clin Sci (Lond). 2016 Jun 1;130(12):1027-38
pubmed: 26993251
Vasa. 2012 Jan;41(1):35-42
pubmed: 22247058
Eur J Vasc Endovasc Surg. 2011 Jan;41 Suppl 1:S1-S58
pubmed: 21215940
Biochim Biophys Acta. 2016 Jul;1861(7):566-83
pubmed: 26968096
Curr Vasc Pharmacol. 2013 May;11(3):305-13
pubmed: 22724484
EBioMedicine. 2019 May;43:43-53
pubmed: 30982767
PLoS One. 2018 Apr 12;13(4):e0195719
pubmed: 29649275
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7
pubmed: 18617650
Thromb Haemost. 2015 Jun;113(6):1335-46
pubmed: 25789510
Circulation. 2006 Mar 21;113(11):e463-654
pubmed: 16549646
J Clin Med. 2019 Dec 26;9(1):
pubmed: 31888089
J Vasc Surg. 2010 Sep;52(3):539-48
pubmed: 20630687
Circulation. 2009 Apr 28;119(16):2202-8
pubmed: 19364978
Methods Mol Biol. 2015;1339:211-33
pubmed: 26445792
Lancet. 2002 Nov 16;360(9345):1531-9
pubmed: 12443589
J Thromb Haemost. 2017 Mar;15(3):575-585
pubmed: 28039962
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2750-2754
pubmed: 30354236
J Am Heart Assoc. 2018 Jan 26;7(3):
pubmed: 29374048
Curr Vasc Pharmacol. 2018 Jan 26;16(2):114-124
pubmed: 28412911

Auteurs

Marina Canyelles (M)

Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.
Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.

Mireia Tondo (M)

Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.

Jes S Lindholt (JS)

Centre of Individualized Medicine in Arterial Disease (CIMA), Department of Cardiology, Odense University Hospital, 5000 Odense, Denmark.

David Santos (D)

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau- IIB Sant Pau, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.

Irati Fernández-Alonso (I)

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau- IIB Sant Pau, 08041 Barcelona, Spain.

David de Gonzalo-Calvo (D)

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau- IIB Sant Pau, 08041 Barcelona, Spain.
Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), 08036 Barcelona, Spain.
CIBER de Cardiovascular (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Luis Miguel Blanco-Colio (LM)

CIBER de Cardiovascular (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.

Joan Carles Escolà-Gil (JC)

Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau- IIB Sant Pau, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.

José Luís Martín-Ventura (JL)

CIBER de Cardiovascular (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.

Francisco Blanco-Vaca (F)

Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.
Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH